TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D for Painful Nocturnal Leg Cramps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One or more prescription for quinine at the Madison VA in the last 5 years, or else be a UWHC (U Wisconsin Health Clinics) patient whose UWHC medication list had quinine listed in the last five years~* At least 50 years of age, with women being past menopause. This is defined as the woman reporting no periods in the last 12 consecutive months or longer.~* Leg cramps listed in medical record,~* Ability \& willingness to give informed consent,~* Stable estimated Glomerular filtration rate (GFR)\>35 ml/min for the prior 6 mos,~* No change in diuretic therapy in last 3 months,~* Stable pattern of two or more cramps per week for past three months,~* Ability to complete daily diary entry,~* Post-consent: serum 25-OH of 20-45 ng/mL, albumin- corrected calcium \<10.3 mg/dL, and urine calcium/creatinine ratio \<0.25.~Exclusion Criteria:~* Not receiving primary care at Madison VAMC, or at UWHC~* Hyperparathyroidism (1°, 2°, or 3°),~* Osteomalacia ,~* Paget's disease,~* Metastatic cancer,~* Taking vitamin D 50,000 units capsules,~* Serum Ca++ \>10.3 mg/dL in subject chart,~* Sarcoidosis or tuberculosis, and~* Peripheral vascular disease or other condition confounding assessment of cramps.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks (Type: EXPERIMENTAL): Vitamin D arm
- placebo x 10d, + placebo weekly 7 wks (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesiologists (ASA) Physical Status 1-3~2. Age greater than or equal to 18 years~3. Scheduled for elective cesarean section~4. English speaking~Exclusion Criteria:~1. ASA Physical Status 4-5~2. Diagnosis of chronic pain~3. Chronic opioid use (opioid use in the past 3 months)~4. Preoperative use of SSRIs (Celexa, Lexapro, Prozac, Paxil), SNRIs (Cymbalta, Effexor), gabapentin, or pregabalin (Lyrica)~5. Inability to cooperate with or understand protocol~6. Inability to communicate pain scores or need for analgesia~7. Infection at the site of block placement~8. Intolerance or allergy to local anesthetics~9. Neurologic deficit or disorder~10. Blood thinning disorder or taking anticoagulant medication~11. BMI \> 50 kg/m2~12. Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years~13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance~14. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TAP block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
- QL block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
- ESP block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven aggressive B-cell non-Hodgkin's lymphoma that has failed prior combination chemotherapy with an anthracycline-containing regimen Eligible histologies: Diffuse large cell Small non-cleaved cell/Burkitt's lymphoma No lymphoblastic or mantle cell lymphoma First relapse or primary refractory disease Ineligible for or refused treatment with salvage chemotherapy followed by high-dose therapy and autologous stem cell rescue Documented CD20 antigen expression Measurable disease No clinical evidence of CNS involvement by lymphoma~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min Other: HIV negative Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior rituximab Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: Recovered from toxic effects of all prior therapy No other concurrent therapy unless disease progression occurs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICE Chemotherapy (Type: ACTIVE_COMPARATOR): Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
- Rituximab-ICE Chemotherapy (Type: EXPERIMENTAL): Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Men and women \>18 years of age.~* Histologically or cytologically confirmed hepatocellular carcinoma or meet imaging criteria for a diagnosis of hepatocellular carcinoma with tumor burden dominant in the liver.~* Participants must have measurable disease, by CT or MRI per mRECIST, not be a candidate for surgical resection based on unresectability, anatomy, anesthesia risk, patient preference.~* Serum Bilirubin ≤ 2.0~* Platelet count \> 50,000/ul (corrected if needed)~* INR ≤ 1.5 (corrected if needed) 9. Serum creatinine \< 2.0 mg/dl~Exclusion Criteria:~* Participants must be at least one month beyond prior chemotherapy, ablation or surgery, and have recovered from all therapy-associated toxicities.~* History of severe allergic reaction to intravenous contrast media (iodinated and gadoliniumbased) or any agents used during the embolization; participant cannot be medicated against allergic reaction prior to embolization or contrast enhanced ultrasound.~* History of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason® microbubbles~* Active infection~* Participants with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)~* Pregnancy or lactation. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.~* Participants may not be receiving any other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumason Microbubbles (Type: EXPERIMENTAL): Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3~  * Planning loop excision or cone biopsy~ * Diagnosis within 2 months prior to study entry~ * Standard histological grading according to Richart~* Visible lesion by colposcopy~  * No unsatisfactory colposcopy or lesions extending into the endocervical canal that cannot be visualized entirely by colposcopy~* No suspicion of invasive cervical cancer by cytology, histology or colposcopy~* No cytologic evidence of glandular atypia or dysplasia~PATIENT CHARACTERISTICS:~* Creatinine normal~* Screening laboratory values within normal range (e.g., complete blood count, liver function tests, renal panel, and electrolytes)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to read and speak English or Spanish~* No known hypersensitivity to bisphosphonates~* Not immunocompromised~* No known HIV positivity~* No aspirin-sensitive asthma due to association of bisphosphonates with bronchoconstriction~* No unexplained abnormal vaginal bleeding~PRIOR CONCURRENT THERAPY:~* No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs, immunosuppressive drugs, or other investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronate (Type: EXPERIMENTAL): 100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone.
- Saline (Type: PLACEBO_COMPARATOR): 100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants with Myelodysplastic Syndrome (MDS) defined according to World Health Organization classification, with Revised International Prognostic Scoring System (IPSS-R) prognostic risk category of intermediate, high, or very high risk.~* Adequate performance status and hematological, liver, and kidney function.~Key Exclusion Criteria:~* Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the investigator, with an available donor.~* Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.~* Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS per IPSS-R.~* Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which participants are not on active anticancer therapies and have had no evidence of active malignancy for at least ≥ 1 year.~* Contraindications to azacitidine.~* Clinical suspicion of active central nervous system (CNS) involvement by MDS.~* Known active or chronic hepatitis B or C infection or human immunodeficiency virus in medical history .~* Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing at screening.~* Pregnancy or active breastfeeding.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magrolimab + Azacitidine (Type: EXPERIMENTAL): Participants will receive the following magrolimab and azacitidine dosing regimens:~Magrolimab:~Magrolimab Priming Dose:~* 1 mg/kg on Days 1 and 4~* 15 mg/kg on Day 8~* 30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)~Magrolimab Maintenance Dose:~* 30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter.~Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle.
- Control Arm (Placebo + Azacitidine) (Type: PLACEBO_COMPARATOR): Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitidine:~Placebo: On Days 1 and 4; Day 8; Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50). Additionally, placebo was administered on Day 57 and every 2 weeks thereafter.~Azacitidine: 75 mg/m\^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Motility Among Diabetes Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: (only patients)~* Subject is suffering from diabetes~* Gastrointestinal symptoms including diarrhoea, nausea, vomiting, bloating and abdominal discomfort)~* Subject \> 18 years of age who possess capacity to understand subject information sheet and give informed consent for participation~* Fasted since midnight until morning 8 o´clock~Exclusion Criteria:~* Dysregulated metabolic disease~* Structuring bowel disease or obvious stenotic symptoms or perforation~* Subject has known swallowing disorders~* Subject has cancer or other life threatening diseases or conditions~* Subject is pregnant or breastfeeding~* Subject has undergone extensive abdominal surgery~* Subject has a abdominal diameter \> 140 cm~* Drug abuse or alcoholism~* Bacterial overgrowth~* Subject has known severe cardiovascular or pulmonary diseases (including artificial pacemaker and/or implantable cardioverter-defibrillator (ICD))~* Central nerve system (CNS) surgery~* Patient have infusion pump or other implantable medical device~* Medication (not possible for pausing for 48 hours) or any other disease affecting motility or/and gastroparesis.~* Subjects having MRI within the next four weeks~* Taking corticosteroids during the last month~* Allergic reaction to Pyridostigmine and/or intravenously administrated contrast~* Severe upper gastrointestinal pathology seen by endoscopy~* Blood glucose below 4 mmol/L or higher than 10 mmol/L right before examination~* Bile acid malabsorption or malabsorption in general~* Obstruction of the urinary system~* Severe renal insufficiency (eGFR \< 45)~* Peritonitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diabetic patient (Type: ACTIVE_COMPARATOR): The study consists of four different parts:~1. 11C Donepezil PET/CT scan~2. 3D-Transit~3. 3D-Transit during treatment with pyridostigmine~4. 3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)
- Healthy subjects (Type: ACTIVE_COMPARATOR): The study consists of two different parts:~1. 11C Donepezil PET/CT scan~2. 3D-Transit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Pulmonary Vein Isolation Efficiency Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American College of Cardiology (ACC)/ American Heart Association (AHA) -Indications for CABG~* At least 2 ECG-verified (12-channel ECG, Holter telemetry) symptomatic paroxysmal atrial fibrillation episodes within last 12 months~* Duration of the atrial fibrillation episode must not exceed 1 week and it must reverse to sinus rhythm spontaneously or by cardioversion~* written and verbal consent~Exclusion Criteria:~* Prior cardiac surgery~* Active pacemaker treatment~* Active anti-arrhythmic treatment(AAD) class I and III~* Contraindication to oral anticoagulant/heparin treatment~* Ejection fraction less than 30 % (EF \< 30 %)assessed by transthoracic echocardiography~* Left atrial diameter less than 55mm assessed by transthoracic echocardiography~* Renal insufficiency requiring dialysis~* Heart valve disease requiring invasive treatment~* Heart anomaly requiring regular controls and/or invasive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CABG, AVR or CABG+AVR and PVI (Type: EXPERIMENTAL): Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
- CABG, AVR or CABG+AVR (Type: ACTIVE_COMPARATOR): Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Aged between 18 and 75 years, extremes included, male or female~* 2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia, according to the official guideline Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)~* 3. Hospitalised with a new onset respiratory illness (≤7 days since illness onset)~* 4. No family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose~* 5. Must agree not to enroll in another study of an investigational agent prior to completion of Day 30 of study~* 6. Informed Consent Form (ICF) signed voluntarily~Exclusion Criteria:~* 1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress, RR ≥ 30 times / min, or SaO2 / SpO2 ≤ 93% in resting state, or arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg (1mmHg = 0.133kpa)~* 2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory failure and mechanical ventilation required, or shock, or combined with other organ failure required ICU monitoring treatment~* 3. Severe liver disease (e.g. Child Pugh score ≥ C, AST \> 5 times upper limit)~* 4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets~* 5. Patients with definite contraindications in the label of ritonavir~* 6. Positive serum pregnancy test result for women with childbearing potential at screening~* 7. Using HIV protease inhibitor drugs~* 8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be transferred to another hospital during the study period, patient with multiple basic diseases, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASC09/ritonavir group (Type: EXPERIMENTAL): ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
- lopinavir/ritonavir group (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues